Vanda Pharmaceuticals Inc... (VNDA)
NASDAQ: VNDA
· Real-Time Price · USD
4.33
0.09 (2.12%)
At close: May 23, 2025, 3:59 PM
4.33
0.02%
After-hours: May 23, 2025, 04:47 PM EDT
Vanda Pharmaceuticals Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fanapt Revenue | 94.3M | 90.87M | 94.73M | 95.15M | 87.48M | 84.21M | 77.28M | 75.11M | 74.35M | 65.62M | 200K |
| Fanapt Revenue Growth | +3.77% | -4.07% | -0.44% | +8.76% | +3.89% | +8.96% | +2.90% | +1.02% | +13.29% | +32711.50% | n/a |
| Hetlioz Revenue | 76.67M | 100.17M | 159.66M | 173.54M | 160.69M | 142.98M | 115.83M | 89.98M | 71.67M | 44.3M | n/a |
| Hetlioz Revenue Growth | -23.45% | -37.26% | -8.00% | +8.00% | +12.38% | +23.43% | +28.74% | +25.54% | +61.78% | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 50.08M | 39.28M | 37.57M | 39.47M | 30.09M | 23.61M | 24.77M | 28.4M | 36.1M | 32.78M | 29.85M | 33M | 40.85M | 33.45M | 32.46M | 28.35M | 29.8M | 35.57M | 34M | 33.92M | 37.02M | 37.02M | 30.22M | 31.47M | 31.03M | 24.92M | 26.05M | 27.96M | 26.82M | 31.05M | 31.12M | 31.37M | 30.3M | 23.91M | 21.91M | 24.68M | 29.29M | 28.88M | 18.46M | 18.39M | 18.81M |
| Selling, General, and Administrative Revenue Growth | +27.50% | +4.55% | -4.82% | +31.21% | +27.41% | -4.66% | -12.79% | -21.34% | +10.13% | +9.81% | -9.54% | -19.21% | +22.13% | +3.05% | +14.50% | -4.87% | -16.23% | +4.62% | +0.25% | -8.38% | +0.01% | +22.49% | -3.96% | +1.41% | +24.50% | -4.32% | -6.84% | +4.24% | -13.61% | -0.24% | -0.79% | +3.54% | +26.73% | +9.12% | -11.24% | -15.73% | +1.42% | +56.47% | +0.39% | -2.23% | n/a |
| Research and Development Revenue | 35.71M | 19.84M | 16.78M | 16.66M | 21.15M | 24.34M | 16.6M | 16.65M | 19.24M | 18.45M | 24.86M | 21.49M | 20.97M | 19.33M | 19.65M | 20.25M | 16.13M | 14.85M | 12.3M | 12.9M | 15.53M | 13.07M | 11.35M | 10.95M | 13.28M | 12.92M | 11.39M | 9.87M | 9.42M | 10.15M | 10.18M | 7.65M | 10.57M | 7.61M | 7.29M | 6.7M | 7.55M | 8.75M | 9.97M | 5.95M | 4.48M |
| Research and Development Revenue Growth | +80.00% | +18.26% | +0.69% | -21.24% | -13.09% | +46.62% | -0.28% | -13.46% | +4.24% | -25.76% | +15.67% | +2.48% | +8.47% | -1.64% | -2.94% | +25.52% | +8.63% | +20.74% | -4.69% | -16.90% | +18.76% | +15.22% | +3.63% | -17.53% | +2.75% | +13.45% | +15.45% | +4.78% | -7.27% | -0.24% | +33.08% | -27.62% | +38.78% | +4.39% | +8.87% | -11.23% | -13.71% | -12.30% | +67.74% | +32.78% | n/a |